Woman with safety glasses
Woman with safety glasses

Our Pipeline

An overview of the clinical studies on our own drug candidates and the most advanced clinical programs of our partners.

Our Pipeline

Latest Update: June 2022

MorphoSys' Clinical Programs

Compound / Brand name
Indication
NCT
Tafasitamab
Target CD19
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (L-MIND) (Monjuvi® - U.S. only – accelerated approval)
Diffuse large B-cell lymphoma (DLBCL) (frontMIND)
Relapsed or refractory follicular or marginal zone lymphoma (FL; MZL) (inMIND)
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (B-MIND)
Diffuse large B-cell lymphoma (DLBCL) (firstMIND)
Pelabresib
BET Inhibitor
Myelofibrosis (MANIFEST-2)
Myelofibrosis (MANIFEST)
Tulmimetostat (CPI-0209)
Target EZH2 Inhibitor
Advanced Solid Tumors / Hematologic Malignancies

Selection of our Partners’ Clinical Programs

Compound / Brand name
Partner
Program
Compound / Brand name
Ianalumab (VAY736)
Partner
Novartis
Program

Ianalumab (VAY736) is a fully human IgG1/k mAb with a dual mode of action targeting B-cell lysis and BAFF-R blockade that is being investigated by Novartis in several indications including Sjögren’s, Autoimmune Hepatitis and Systemic Lupus Erythematosus (SLE). Ianalumab is currently in phase 3 clinical development in Lupus Nephritis and Sjögren’s.

Compound / Brand name
Abelacimab (MAA868)
Partner
Anthos Therapeutics
Program

Abelacimab (MAA868) is an antibody directed against Factor XI that is being investigated by Anthos Therapeutics in two complimentary phase 3 clinical studies in cancer associated thrombosis (CAT) for the prevention of venous thromboembolism (VTE).

Compound / Brand name
Setrusumab (BPS804)
Partner
Mereo Biopharma and Ultragenyx
Program

Setrusumab (BPS804) is an antibody directed against sclerostin that is currently being investigated by Ultragenyx and Mereo Biopharma in a phase 2/3 clinical study for the treatment of osteogenesis imperfecta.

Compound / Brand name
Felzartamab
Partner
HIBIO-I-Mab
Program

Felzartamab is a therapeutic human monoclonal antibody directed against CD38. Human Immunology Biosciences, Inc. (HI-Bio) obtained exclusive rights to develop and commercialize felzartamab across all indications worldwide, with the exception of Greater China. On behalf of HI-Bio, MorphoSys is evaluating felzartamab for patients with two renal autoimmune diseases, anti-PLA2R antibody-positive membranous nephropathy (M-PLACE and NewPLACE trial) and Immunoglobulin A Nephropathy (IGNAZ trial). I-Mab Biopharma holds the exclusive regional rights to develop and commercialize felzartamab in Greater China and is studying felzartamab in relapsed/refractory multiple myeloma.

Compound / Brand name
NOV-8 (CMK389)
Partner
Novartis
Program

NOV-8 (CMK389) is being investigated by Novartis for the treatment of pulmonary sarcoidosis (Phase 2) and severe atopic dermatitis (also Phase 2).

Compound / Brand name
Bimagrumab
Partner
Versanis Bio
Program

Bimagrumab is currently being investigated by Versanis Bio in Phase 2b study as a novel treatment for obesity

Compound / Brand name
NOV-9 (LKA651)
Partner
Novartis
Program

NOV-9 (LKA651) is also currently being investigated by Novartis in Phase 2 for the treatment of diabetic eye diseases.

Compound / Brand name
NOV-14 (CSJ117)
Partner
Novartis
Program

NOV-14 (CSJ117) is currently under investigation by Novartis for the treatment of chronic obstructive pulmonary disease (COPD) in Phase 2.

Compound / Brand name
MOR210
Partner
HIBIO-I-Mab
Program

MOR210 is a human antibody directed against C5aR1, the receptor of the complement factor C5a. Human Immunology Biosciences (HI-Bio) obtained exclusive worldwide rights to develop and commercialize MOR210 across all indications worldwide, with the exception of Greater China and South Korea. I-Mab Biopharma holds the exclusive rights for MOR210 in Greater China and South Korea and is currently investigating MOR210 for the treatment of relapsed or refractory advanced solid tumors (Phase 1).

A mother and daughter hugging

Clinical Trials

Patients are kindly asked to contact their treating physicians if they are interested in participating in any of MorphoSys' clinical trials.

A mother and daughter hugging